MediGene AG To Participate In Three Upcoming International Conferences
Martinsried/Munich, 02 March, 2015. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in three upcoming scientific and business development conferences:
• BIO-Europe Spring 2015 - 9th Annual International Partnering Conference
Date: 09 - 11 March 2015
Location: Paris, France
• 9. Forum Life Science
Date: 11 - 12 March 2015
Location: Munich, Germany
Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG will conduct a presentation on 12 March titled "The power of T cells in terms of cancer therapy"
• 26th Annual Cancer Progress Conference
Date: 17 - 18 March 2015
Location: New York, USA
Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG will be panelist at a discussion on 17 March focussing the topic "Immunotherapy II: Engineered Cell Therapy"
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com
• BIO-Europe Spring 2015 - 9th Annual International Partnering Conference
Date: 09 - 11 March 2015
Location: Paris, France
• 9. Forum Life Science
Date: 11 - 12 March 2015
Location: Munich, Germany
Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG will conduct a presentation on 12 March titled "The power of T cells in terms of cancer therapy"
• 26th Annual Cancer Progress Conference
Date: 17 - 18 March 2015
Location: New York, USA
Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG will be panelist at a discussion on 17 March focussing the topic "Immunotherapy II: Engineered Cell Therapy"
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com